Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.46 |
| ▸ | PI4KA | P42356 | 2/20 | 0.46 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.46 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.46 |
| ▸ | FLT4 | P35916 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22399690 | 0.89 | ADORA2A (0.49) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL22399611 | 0.89 | ADORA2A (0.49) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL6364118 | 0.85 | ADORA2A (0.60) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL19350814 | 0.81 | ADORA2A (0.48) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL5699095 | 0.77 | FLT4 (0.46) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL4379586 | 0.75 | ADORA1 (0.56) | ADORA2AADORA1FLT4KDRTAAR1 | |
| SCHEMBL21127815 | 0.74 | ADORA2A (0.46) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL19987154 | 0.74 | FLT4 (0.46) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL9503851 | 0.74 | FLT4 (0.49) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL24205301 | 0.73 | FLT4 (0.43) | ADORA2AADORA1ADORA2BPI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759825-B2 | Cyclic di-nucleotide compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10738074-B2 | Cyclic di-nucleotide compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738074-B2 | Cyclic di-nucleotide compounds as STING agonists | STING1, CGAS, IFNAR1 | ADORA2A 72/4885ADORA1 36/4885ADORA2B 150/4885 |
| US-10759825-B2 | Cyclic di-nucleotide compounds as STING agonists | STING1, CGAS, IFNAR1 | ADORA2A 73/4885ADORA1 32/4885ADORA2B 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.